Vinpocetine

General characteristics. Structure:

Active agent: Vinpocetine of 5 mg/ml.
Excipients: propylene glycol, citric acid, sorbitol, sodium disulphite, sodium sulfite, эдетат dinatrium, Acidum hydrochloricum, water for injections.

Description: The transparent slightly painted liquid.

Pharmacological properties:

Pharmacodynamics. Possesses vasodilating, anti-hypoxemic and anti-modular action. Inhibits phosphodiesterase and increases the content of cyclic adenosinemonophosphate in cells that in turn, leads to decrease in content of calcium in cytoplasm of smooth muscle cells and to relaxation of myofibrils. Combines vascular and metabolic action. Expands brain vessels, strengthens a blood stream, it is preferential in ischemic areas, improves supply of a brain with oxygen. Promotes utilization of glucose and increases the level of catecholamines in the central nervous system, stimulates metabolism of noradrenaline and serotonin in brain tissues. Reduces aggregation of thrombocytes, viscosity of blood, promotes increase in deformability of erythrocytes and normalization of venous outflow against the background of decrease in resistance of brain vessels. System arterial pressure slightly goes down. Efficiency in the acute period of a stroke: accelerates regress of all-brain and focal neurologic symptomatology, improves memory, attention, intellectual productivity. Sensitivity of brain vessels to the running-down action of a Vinpocetine increases in advanced and senile age that is caused by a sensitization of system of adenylatecyclase – cyclic adenosinemonophosphate when aging.

Pharmacokinetics. At parenteral administration easily gets through gistogematichesky barriers (including through a blood-brain barrier). The volume of distribution makes 5,3 l/kg of body weight. The elimination half-life is equal to 4,75 h.

Indications to use:

Acute and chronic forms of insufficiency of cerebral circulation (tranzitorny ischemic attacks, acute and residual stages of a stroke, encephalopathy);

the mental and neurologic disturbances connected with cerebrovascular insufficiency (dysmnesias, dizziness, a headache, aphasia, apraxia, motive frustration);

in ophthalmology: at vascular diseases of a retina and/or a choroid of an eye; at the degenerative changes of a macula lutea caused by atherosclerosis or a vasomotor spasm; at partial occlusion of vessels, secondary glaucoma;

in otolaryngology at senile relative deafness, Menyer's disease, deterioration in hearing vascular or toxic (including medicamentous) genesis, at dizzinesses of a labyrinth origin.

Route of administration and doses:

Intravenously kapelno. 20 mg part in 250-400 ml of infusion solution. At good tolerance the drug dose within 3-4 days is raised to 1 mg/kg, treatment is continued within 10-14 days. After the termination of a course of parenteral administration pass to oral administration of drug. Before drug withdrawal the dose should be reduced gradually.

Side effects:

Dizziness, feeling of heat, dermahemia of the person, nausea. From cardiovascular system the tranzitorny lowering of arterial pressure, tachycardia, premature ventricular contraction, increase in time of excitement of ventricles, thrombophlebitis in an injection site can be observed.

Interaction with other medicines:

Increases risk of development of hemorrhagic complications against the background of a geparinoterapiya. Vinpocetine solution is pharmaceutical not compatible to heparin.

Contraindications:

Hypersensitivity; the expressed coronary heart disease; severe forms of disturbance of a heart rhythm; acute phase of a hemorrhagic stroke; pregnancy and period of a lactation.

Storage conditions:

Period of validity: 2 years. Not to use on expiry date, specified on packaging. List B. In the place protected from light at a temperature not above 25 °C. To store in the place, unavailable to children.

Issue conditions:

According to the recipe

Packaging:

Concentrate for preparation of solution for infusions of 5 mg/ml. On 2 ml in ampoules of light-protective glass. On 5 ampoules in a blister strip packaging. On the 2nd blister strip packagings together with the application instruction in a pack cardboard.